GC Biopharma Corp

GC Biopharma Corp maintains a debt-to-equity ratio of 0.81, indicating a moderate reliance on debt financing, while its current ratio of 1.2 suggests limited short-term liquidity cushion. The company's price-to-book ratio of 1.26 and price-to-tangible-book ratio of 1.26 reflect a valuation in line with tangible asset backing, but its negative net income of -4.67 billion KRW and free cash flow of -66.5 billion KRW highlight operational cash flow challenges. The enterprise value to EBITDA ratio of 151.69 is significantly elevated, suggesting a high premium for earnings potential amid current losses. Profitability metrics reveal a deteriorating performance, with a return on equity of -0.38% and return on assets of -0.16%, both well below the industry median for pharmaceutical firms. The company's operating margin of 0.82% (16.26 billion KRW operating income on 1.99 trillion KRW revenue) is a fraction of the sector average, and its net loss of 4.67 billion KRW contrasts sharply with the industry's positive net income norms. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of segmental or geographic diversification increases exposure to market-specific risks, particularly in South Korea, where the company is headquartered and likely derives the majority of its sales. Outlook data indicates a projected revenue increase of 12.4% in the current fiscal year, driven by the commercialization of new oncology products. However, the next fiscal year is expected to see a 3.2% decline in revenue, reflecting anticipated market saturation and pricing pressures in the biopharmaceutical sector. The company's capital expenditure of -105.28 billion KRW suggests a significant investment in R&D and manufacturing infrastructure, which may support long-term growth but is currently straining cash flow. Risk assessment highlights medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk based on current share structure. The company's long-term debt of 982.14 billion KRW represents 56% of total liabilities, and its cash and equivalents of 49.37 billion KRW are insufficient to cover immediate obligations. No recent filings or transcripts indicate material changes in strategy or operations, though the company's ongoing R&D pipeline remains a key focus for future growth.